BIIB•benzinga•
European Drug Regulator Gives Thumbs Down To Eli Lilly's Alzheimer's Drug, Analyst Says It Is Incremental Win For Biogen
Summary
Eli Lilly's donanemab faces a setback as EMA's CHMP issues a negative opinion. Analysts expect Lilly to appeal, citing past reversals in similar cases.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on March 28, 2025 by benzinga